Regenxbio Inc (NAS:RGNX)
$ 10 0.08 (0.81%) Market Cap: 495.45 Mil Enterprise Value: 320.09 Mil PE Ratio: 0 PB Ratio: 1.64 GF Score: 65/100

Regenxbio Inc at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 06:35PM GMT
Release Date Price: $57.79 (+0.52%)
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang, I'm a mid-cap biotech analyst at Barclays. It is my great pleasure to introduce our next speaker, Ken Mills from REGENXBIO.

Kenneth T. Mills
REGENXBIO Inc. - CEO, President & Director

Thanks, Gena. Good afternoon, everyone. Appreciate the opportunity that Gena and the team have afforded us to present on REGENXBIO today. Forward-looking statements and risk factors can be found in more detail in our disclosures on the SEC website.

REGENXBIO: People, plan, science and the mission. Seeking improved lives through the curative potential of gene therapy, the people at REGENXBIO and our partners are currently focused on over 30 programs in preclinical or clinical stages. Inside the company, we have 200 people in Rockville, Maryland, focused on advancing 4 clinical-stage programs. Outside through partnership, we have over 14 clinical-stage programs with some of the most advanced programs on the cusp of a punitive approval here in the first

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot